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Signaling between tumor cells and the associated stroma has an important impact on
cancer initiation and progression. The tumor microenvironment has a paradoxical role in
tumor progression and fibroblasts, a major component of the tumor stroma, have been
shown to either inhibit or promote cancer development. In this study, we established that
normal intestinal fibroblasts activate STAT1 signaling in colon cancer cells and, in contrast
to cancer-associated fibroblasts, inhibit growth of tumor cells. Treatment of 18Co fibrob-
lasts with the proinflammatory cytokine TNFα interfered with their ability to trigger STAT1
signaling in cancer cells. Accordingly, intestinal myofibroblasts isolated from patients with
ulcerative colitis or Crohn’s disease, which are activated and produce high levels of TNFα,
failed to stimulate STAT1 signaling in tumor cells, demonstrating that activated myofibrob-
lasts lose the ability to trigger growth-inhibitory STAT1 signaling in tumor cells. Finally, we
confirmed that silencing of STAT1 in tumor cells alters the crosstalk between tumor cells
and fibroblasts, suggesting STAT1 as a novel link between intestinal inflammation and colon
cancer. We demonstrated that normal fibroblasts restrain the growth of carcinoma cells,
at least in part, through the induction of STAT1 signaling in cancer cells and showed that
changes in the microenvironment, as they occur in inflammatory bowel disease, alter the
crosstalk between carcinoma cells and fibroblasts, perturb the homeostasis of intestinal
tissue, and thereby contribute to tumor progression.
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INTRODUCTION
Progression of colon cancer relies on the communication of tumor
cells with the adjacent stroma. Reciprocal interactions between
tumor cells and stroma are mediated by soluble factors such as
cytokines, growth factors, chemokines, proteases, and components
of the extracellular matrix. Fibroblasts and myofibroblasts are the
major stromal cell types associated with human carcinomas.
Cancer-associated fibroblasts (CAFs) have a role in both initi-
ation and progression of cancer. The origin of CAFs and myofi-
broblasts is poorly understood. Experimental data suggest that
myofibroblasts can be derived from epithelial cells via epithe-
lial mesenchymal transition, they can differentiate from resident
fibroblasts, adipocytes, or from mesenchymal or hematopoietic
stem cells (1). Several tumor-derived factors, including TGFβ,
have been shown to mediate the conversion of normal fibroblasts
into CAFs (2). Tumor-associated fibroblasts are similar to fibrob-
lasts found in wounded and fibrotic tissues. However, in contrast
to wound healing, where activated fibroblasts revert to a quies-
cent phenotype once the process is completed, tumor-associated
fibroblasts remain constitutively activated and thus aid in tumor
growth and tumor survival. CAFs remain non-transformed, there-
fore genetic alterations are unlikely to contribute to their ability
to drive tumor progression (3). They have been shown to support
the survival and proliferation of cancer cell and to stimulate their
invasiveness and metastasis (4, 5). CAFs retain their properties
in vitro without contact with carcinoma cells (6); whether they
maintain the activated state due to epigenetic changes has not yet
been determined.
Induction of DNA damage in fibroblasts by irradiation
increases their ability to aid tumor development (7). Genotoxic
agents used for cancer therapy have been shown to induce Wnt16
in fibroblasts, which – in a paracrine manner – activates Wnt sig-
naling in tumor cells and thus attenuates the efficacy of cytotoxic
chemotherapy (8). Similarly, senescent fibroblasts, which are char-
acterized by a proinflammatory phenotype and persistent DNA
damage, have potent tumor-promoting activity (9–12). Notably,
while senescent fibroblasts have no effect on normal epithelial
cells, they enhance proliferation of malignant and premalignant
epithelial cells (11).
In contrast to CAFs, normal fibroblasts are required to maintain
tissue homeostasis and they have been shown to control abnormal
growth of pre-neoplastic cells and to restrain tumor progression.
For example, inactivation of the TGFβ type II receptor in fibrob-
lasts was sufficient to initiate prostate intraepithelial neoplasia
(PIN), confirming that normal fibroblasts can block tumor initia-
tion (5, 13). However, the mechanisms whereby normal fibroblasts
inhibit tumor initiation/progression remain unknown.
Tumor cells communicate with the stroma through soluble fac-
tors such as cytokines, chemokines, and growth factors. A number
of cytokines mediate their responses through activation of the
www.frontiersin.org April 2014 | Volume 4 | Article 88 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kaler et al. Fibroblasts, STAT1, and colon cancer
JAK/STAT pathway. STATs (STAT1–STAT6) are latent cytoplasmic
transcription factors that transduce signals to the nucleus where
they activate transcription, and thereby regulate the expression
of a variety of target genes. STAT1 is the founding member of
the STAT family. IFNγ was the first cytokine shown to activate
STAT1 signaling (14, 15) and STAT1 has been shown to mediate
the anti-proliferative activity of IFNs (16). We and others have
shown that lack of STAT1 expression perturbs the induction of
p21 in response to 5-Aza-CdR (17), to inhibitors of HDAC activ-
ity (18), and to camptothecin (Klampfer et al., unpublished). p21
is an inhibitor of cell cycle progression and its regulatory region
harbors multiple STAT1 binding sites, suggesting that STAT1 sup-
ports transcriptional activation of p21 in response to these agents
(19). STAT1 has been suggested to have tumor-suppressor proper-
ties (20) and expression of STAT1 suppressed the tumorigenicity of
RAD-105 cells in vivo, which correlated with decreased expression
of proangiogenic molecules such as bFGF, MMP-2, and MMP-
9 (21). Although the role of STAT1 in tumorigenesis appears to
be complex, these findings demonstrate that STAT1 can act as an
inhibitor of tumor progression by restraining tumor growth and
metastasis.
In this study, we compared the ability of normal intestinal
fibroblasts and myofibroblasts isolated from Crohn’s disease (CD),
ulcerative colitis (UC), or colon cancer patients, to regulate the
growth of colon cancer cells. We show that normal fibroblasts
inhibit proliferation of colon cancer cells and that myofibroblasts
isolated from a CD patient, which fail to induce STAT1 signaling
in tumor cells, lack this inhibitory activity. We demonstrated that
activation of fibroblasts with TNF, a cytokine with a central role in
the pathogenesis CD, is sufficient to reduce their ability to induce
STAT1 signaling in tumor cells. Fibroblasts failed to inhibit growth
of STAT1-deficient tumor cells, confirming a crucial role of STAT1
for the crosstalk between tumor cells and fibroblasts.
MATERIALS AND METHODS
CELL LINES AND CO-CULTURE EXPERIMENTS
The HCT116 and Hke-3 colorectal carcinoma cell lines, which dif-
fer only by the presence of the mutant K-Ras allele (22), were cul-
tured in MEM containing 10% FBS. Rat intestinal epithelial cells
(IEC-6), transfected with an inducible K-Ras Val-12 cDNA (IEC-
iK-Ras), were a generous gift from Dr. Raymond DuBois (23).
Cells were maintained in Dulbecco’s modified Eagle’s medium
containing 10% fetal bovine serum, 400µg/ml G418 (Invitrogen),
and 150µg/ml hygromycin B (Sigma). Expression of oncogenic
Ras was induced by 5 mM IPTG (Calbiochem). MIC216 cells,
a kind gift of Michele Dr. Kedinger (Universite Louis Pasteur,
Paris), were maintained in DMEM medium with 10% FBS and
human intestinal 18Co fibroblasts (ATCC) in MEM supplemented
with 10% FBS. HIF myofibroblasts isolated from a normal donor
(HIF ND) and myofibroblasts isolated from a CD patient and an
UC patient were a generous gift from Dr. Claudio Fiocchi, The
Cleveland Clinic Foundation (24–26). Conditioned media were
prepared from sub-confluent fibroblast cultures maintained in
MEM containing 10% FBS, centrifuged to remove cell debris and
were used immediately or were stored at−80°C. Supernatants col-
lected from CAF were provided by Dr. Mahida, University Hospital
Nottingham, UK.
Transwell permeable supports with 0.4µM pores (Corning
Incorporated, Lowell, MA, USA) were used in co-culture experi-
ments, which were performed as described before (27, 28). Briefly,
HCT116 colon cancer cells were co-cultured with fibroblasts in
a 1:1 ratio for 24 h. Human TNFα and IFNγ were purchased
from Biosource Life Technologies. Cells were treated with TNF
(5 ng/ml) or IFNγ (5 ng/ml) for 24 h. Phosphorylation of STAT1
(STAT1–Y701) was determined 1 h after treatment with IFNγ
(Figure 2C).
Cell growth was assessed by the MTT assay, by BrdU incorpo-
ration (BrdU cell proliferation Assay kit, Calbiochem, Gibbstown,
NJ, USA) or by CellTiter-Glo Luminescent assay (Promega). The
assays were performed according to the manufacturer’s instruc-
tions. For all assays, 1× 104 cells/100µl were plated into 96 well
plates alone or in the presence of fibroblast conditioned medium
(CM) as indicated. For the MTT assay, 10µl of MTT reagent
(5 mg/ml) was added to cells for 4 h, and cells were lysed overnight
with 0.01 N HCL in 10% SDS. Absorbance wad read at 570 nm,
using 630 nm as a reference. For the BrdU incorporation assay, cells
were labeled with BrdU for 8 h, fixed and incubated with an anti-
BrdU antibody (1:100) for 1 h at room temperature. After 30 min
incubation with HRP-labeled antibody, substrate was added for
15 min and absorbance was read at dual wavelength (450–540 nm).
The CellTiter-Glo reagent was added to equal volume of the cell
culture medium and cultures were mixed for 2 min on an orbital
shaker to induce cell lysis. After further incubation for 10 min,
luminescence was measured using the plate reader. In all cases,
experiments were performed in triplicate.
TRANSIENT TRANSFECTION AND REPORTER GENE ASSAY
HCT116 and Hke-3 cells were transiently transfected using the
calcium phosphate method (Promega). The plasmids used in the
manuscript were described before. 8XGAS-LUC and 3XAP1-LUC
plasmids were provided by Dr. Christopher Glass and the TOP-
FLASH promoter construct by Dr. Vogelstein. In all cases, cells
were transfected with 1µg of the test plasmid DNA and 0.1µg
of TK-renilla to control for transfection efficiency and viability.
Transfected cells were cultured alone or together with fibrob-
lasts for 24 h. The luciferase and renilla activity were determined
according to the vendor’s protocol (Dual Luciferase reporter assay,
Promega, Madison, WI, USA).
HCT116 cells were transfected with a pool of four siRNAs
(Dharmacon) specific for the human STAT1 gene using the Pro-
fection Mammalian Transfection Systems (Promega, Madison,WI,
USA) as we described before (18, 29, 30). Non-specific (NSP), non-
targeting siRNA, was used as control. Both STAT1 and NSP siRNAs
were delivered at a concentration of 25 nM.
WESTERN BLOTTING
Immunoblotting was performed using standard procedures.
Membranes were blocked with 5% milk in TBS containing 0.1%
Tween 20, and incubated with antibodies specific for cyclin D1
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), pSTAT1,
COX2, IRF1 (Millipore, Billerica, MA, USA), and β-actin (Sigma
Aldrich, St. Louis, MO, USA). Immunoreactive bands were visual-
ized by chemiluminescence (Amersham ECL™ western blotting
detection kit, Piscataway, NJ, USA).
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PROTEOME PROFILER, HUMAN CYTOKINE ANTIBODY ARRAY
The levels of cytokines were determined in supernatants collected
from untreated 18Co cells or from 18Co cells that were treated
with TNF (5 ng/ml) for 24 h. Relative cytokines levels were deter-
mined using Proteome Profiler, Human Cytokine Array kit (R&D
Systems, Minneapolis, MN, USA) according to the manufacturer’s
instructions. Supernatants were used immediately or were stored
at −80°C and were incubated with human cytokine array panel
antibody cocktail at room temperature for 1 h. After blocking, the
membranes were incubated with supernatants at 4°C overnight on
a rocking platform. Membranes were incubated with streptavidin–
HRP for 30 min at room temperature and developed with Chemi
Reagent Mix according to the manufacturer’s instructions.
GENERATION OF 3D SPHEROIDS BY HANGING DROP CELL CULTURE
HCT116 cells were trypsinized and resuspended in a complete
MEM medium at a concentration of 1× 106 cells/ml. Ten micro-
liters of the cell suspension were deposited on the lid of the 100 mm
tissue culture dish, which was subsequently inverted onto the PBS-
filled bottom chamber. Cells were incubated at 37°C and 5% CO2
for 5–7 days and the formation of spheroids was monitored on a
daily basis.
RESULTS
INTESTINAL FIBROBLASTS INDUCE STAT1 SIGNALING IN COLON
CANCER CELLS
While the protumorigenic nature of CAFs is well studied, little
is known about the nature of the crosstalk between tumor cells
and normal, tumor-inhibitory stroma. To establish the mecha-
nism whereby normal intestinal fibroblasts regulate the growth
of colon cancer cells, we transfected HCT116 cells with reporter
genes measuring the activity of major signaling pathways, includ-
ing AP1, NFκB, Wnt, and STAT1. Transfected cells were cultured
in the absence or the presence of 18Co intestinal fibroblasts
(1× 105/well of a 12 well plate) for 24 h. Treatment of cells with 12-
O-tetradecanoylphorbol-13-acetate (TPA, 10 ng/ml) served as a
positive control for AP1-driven transcriptional activity, treatment
with TNFα (5 ng/ml) for NFκB and with sodium butyrate (Bu,
5 mM) for the Wnt-driven transcriptional activity. 18Co cells did
not impact the activity of NFκB, Wnt, AP1-driven signaling path-
ways (Figures 1A and 1B), however, we showed that fibroblasts – in
a dose-dependent manner – enhanced STAT1-driven transcrip-
tional activation in tumor cells (Figure 1C). Activation of STAT1
transcriptional activity by 18Co cells was cell-type specific, as
we published before that macrophages failed to modulate STAT1
transcriptional activity in colon cancer cells (data not shown) (27).
In contrast to normal fibroblasts, activated fibroblasts produce
a number of soluble factors. For example, myofibroblasts isolated
from CD patients produce increased levels of TNF, which acts in
an autocrine and paracrine manner and plays a major role in the
pathogenesis of CD (31, 32). First, we tested whether activation
of 18Co cells with TNF, or with LPS, a known inducer of inflam-
matory mediators, alters their ability to activate STAT1 activity
and their crosstalk with tumor cells. HCT116 cells were trans-
fected with the GAS-LUC reporter gene and were cultured alone
or together with 18Co cells in the absence or the presence of TNF
FIGURE 1 | 18Co intestinal fibroblasts induce STAT1 signaling in carcinoma cells. HCT116 cells were transfected with reported genes for AP1 (A), NFκB,
Wnt (TOP-FLASH) (B), or STAT1 (GAS, gamma activated sequence) and were cultured alone or in the presence of 18Co cells. (C) HCT116 cells transfected with
GAS-LUC were cultured in the presence of increasing number of 18Co cells as indicated. *p=< 0.01 versus control cells; NS, non-significant.
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FIGURE 2 | Fibroblasts induce STAT1 signaling in tumor cells.
(A) HCT116 cells transfected with GAS-LUC were treated as indicated,
(B) HCT116 and Hke-3 cells were transfected with GAS-LUC and were
co-cultured with 18Co cells, fibroblasts isolated from a normal donor
(HIF ND), a patient with ulcerative colitis (HIF UC) or Crohn’s disease
(CD). (C) HCT116 and Hke-3 cells were co-cultured with 18Co, HIF, or
CD myofibroblasts and the levels of pSTAT1 and IRF1 were
determined by immunoblotting. *p=<0.05 versus control cells; NS,
non-significant; #p< 0.02; **p<0.01 versus 18Co and HIF ND
fibroblasts.
(5 ng/ml) or LPS (10 ng/ml) for 24 h. Cells were co-transfected
with TK-renilla to monitor for transfection efficiency and cell via-
bility, and the results were expressed as the ratio between luciferase
and renilla (LUC/REN). As shown in Figure 2A, treatment with
TNF, but not LPS, completely prevented the ability of 18Co cells
to trigger STAT1 activation in HCT116 cells.
To exclude the possibility that activation of STAT1 signaling was
specific for 18Co cells, we used another line of normal intestinal
fibroblast. We compared the ability of human intestinal fibroblasts
isolated from normal mucosa (HIF ND) and myofibroblasts iso-
lated from a patient with UC or CD, risk factors for colon cancer, to
activate STAT1 in colonic epithelial cells. Like 18Co cells, normal
HIFs induced STAT1 activation in both HCT116 and Hke-3 cells.
The ability of myofibroblasts isolated from UC or CD patients to
activate STAT1 signaling in tumor cells was significantly reduced
compared to 18Co and HIF ND fibroblasts (Figure 2B).
Consistent with the results shown in Figure 2B, HCT116 and
Hke-3 cells that were co-cultured with normal fibroblasts, but not
myofibroblasts isolated from a CD patient, showed increased lev-
els of pSTAT1 (Y701), confirming that fibroblast-derived factor(s)
induce STAT1 activation in tumor cells (Figure 2C). HCT116 cells
treated with IFNγ for 1 h served as a positive control for STAT1
phosphorylation.
18Co cells produce several cytokines/chemokines (Figure 3A)
that could, in a paracrine manner, contribute to STAT1 activation
in intestinal cells. Treatment of 18Co cells with TNF induced the
synthesis of a number of protumorigenic soluble factors, includ-
ing sICAM1 (CD54), C5a, CCL5, GM-CSF, and IP10 (Figure 3A).
The expression of IL6 significantly increased and, surprisingly, the
expression of IL8 decreased upon TNF treatment. Whether any of
these factors interfere with the STAT1 activity remains to be deter-
mined. More comprehensive analysis of soluble factors will be
required to determine how fibroblast-derived factors regulate the
growth of tumor cells and how TNF alters the signaling between
tumor cells and fibroblasts. For example, we showed that both TNF
and IL1, another proinflammatory cytokine, are potent inducers
of COX2 expression in 18Co cells (Figure 3B), which could, by
stimulating prostaglandin synthesis, further impact the crosstalk
between tumor cells and stroma.
NORMAL INTESTINAL FIBROBLASTS, BUT NOT MYOFIBROBLASTS
ISOLATED FROM A CROHN’S DISEASE PATIENT, INHIBIT THE GROWTH
OF COLON CANCER CELLS
Next, we examined how fibroblasts impact the growth of human
colon cancer cells. Furthermore, to establish whether oncogenic
transformation of intestinal epithelial cells with activated K-Ras
alters their crosstalk with fibroblasts, we performed experiments in
both HCT116 and Hke-3 cells. HCT116 cells harbor a mutant K-
Ras V12 allele, and Hke-3 cells are an isogenic derivative, generated
by the targeted deletion of the dominantly acting mutant K-Ras
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FIGURE 3 | Activation of 18Co cells withTNF stimulates the synthesis
of a number of protumorigenic factors. (A) 18Co cells were left untreated
or were treated with TNF for 24 h and the proteome profiler antibody array
(R&D Systems) was performed. Circled are positive controls. (B) 18Co cells
were stimulated with TNF, IL1, IFNγ, or LPS as indicated and the amount of
COX2 was determined by immunoblotting.
allele in HCT116 cells (22). Cancer cells were grown in the pres-
ence of control medium or CM from normal intestinal fibroblasts
(18Co cells), and the viability of tumor cells was monitored by the
MTT assay. As shown in Figure 4A, 18Co cells secrete factors that,
in a dose-dependent manner inhibited the growth of colon can-
cer cells. We confirmed that HIFs, another line of normal human
intestinal fibroblasts also inhibited the growth of HCT116 cells
(Figure 4B). The results were confirmed by the BrdU incorpora-
tion assay (data not shown). In marked contrast, myofibroblasts
isolated from a CD patient, which failed to activate STAT1 signal-
ing in tumor cells (Figure 2), had lost the ability to inhibit the
growth of tumor cells (Figure 4B).
Significantly, the growth-inhibitory effect of both 18Co and
HIF fibroblasts was more pronounced in HCT116 cells, which
carry mutant K-Ras, than in HKe-3 cells (Figure 4A, data not
shown). Similar results were obtained using rat intestinal epithelial
cells with inducible K-Ras expression (Figure S1 in Supplementary
Material).
In contrast to the majority of established cell lines, the HCT116
cell line shows limited heterogeneity and has been proposed to con-
sist of mostly stem cells (33). Indeed, HCT116 cells readily form
spheroids, confirming their stem-cell phenotype. We showed that
soluble factors produced by 18Co cells diminished the ability of
HCT116 cells to form spheroids (Figure 4C). Similarly, if we gener-
ated spheroids by co-culture of HCT116 and 18Co cells, the size of
spheroids was significantly reduced and we did not observe large,
compact spheroids, as typically formed by HCT116 cells. This
confirmed the negative effect of fibroblast-derived factors on car-
cinoma cells and suggested that fibroblast-derived factors regulate
the stemness of carcinoma cells. In contrast, macrophage-derived
factors, which induce Wnt signaling and promote the growth of
HCT116 cells (27, 28), did not interfere with the spherogenic
potential of HCT116 cells (Figure 4C).
Finally, we investigated how CAFs regulate the growth of
HCT116 and Hke-3 cells. Tumor cells were grown in the absence or
the presence of CM from cancer-associated myofibroblasts (kindly
provided by Dr. Mehida, University Hospital Nottingham, UK)
and the growth and proliferation of the cancer cells was monitored
by the MTT assay and BrdU incorporation. In contrast to normal
myofibroblasts, which inhibited proliferation of cancer cells, we
confirmed that factors produced by CAFs promoted growth of
both HCT116 and Hke-3 cells (Figure 5), consistent with their
protumorigenic activity.
FIBROBLASTS INHIBIT GROWTH OF COLON CANCER CELLS IN A
STAT1-DEPENDENT MANNER
To demonstrate that factors produced by normal fibroblasts reg-
ulate the growth of tumor cells through STAT1 activation, we
silenced STAT1 in HCT116 cells. Efficiency of STAT1 silencing
was confirmed by immunoblotting (Figure 6B); STAT1 deficiency
did not have a significant impact on the growth of HCT116 cells.
Next, we compared the ability of 18Co fibroblasts to modulate the
growth of HCT116 cells that were transfected with NSP or STAT1
specific RNAi. As shown before (Figure 4), fibroblasts-derived
factors inhibited proliferation of HCT116 cells transfected with
NSP RNAi. However, the ability of fibroblasts to inhibit growth
was significantly diminished in HCT116 cells transfected with
STAT1 RNAi (Figure 6A). While fibroblast-derived factor reduced
the viability of HCT116 cells transfected with non-targeted RNAi
to 45–50%, HCT116 cells transfected with STAT1-specific RNAi
retained 80–89% viability in the presence of fibroblast-derived fac-
tors (Figure 4). These results confirmed that fibroblasts restrain
the growth of tumor cells, at least in part, through activation of
STAT1.
DISCUSSION
Although tumor progression is commonly driven by the accumu-
lation of somatic mutations, it has been established that tumor
cells become addicted not only to oncogenes, but also to support-
ive signals they receive from the tumor microenvironment. While
fibroblasts are the predominant cell type in the lamina propria of
normal colon, they are replaced by myofibroblasts in hyperplas-
tic and neoplastic polyps, confirming a role of myofibroblasts in
colorectal neoplasia. Carcinoma cells recruit normal fibroblasts
and secrete factors that promote their conversion into myofibrob-
lasts. Among tumor-derived factors that activate fibroblasts are
TGFβ, PGE, TNF, IFNγ, and IL6. In turn, activated fibroblasts
secrete HGF, CCL7, UPAR, VEGF, and other factors that promote
stemness,growth, survival, and invasiveness of tumor cells (34,35).
CAFs isolated from invasive tumors share similarities with myofi-
broblasts, such as high expression of αSMA and increased collagen
contractility.
In contrast, normal stromal cells have been shown to pro-
duce factors that inhibit the progression of epithelial malignan-
cies (36,37,38) and it has been proposed that a normal tissue
microenvironment serves as a barrier to cancer (38). Indeed, nor-
mal stroma appears to impede tumor development. However,
much less is known about signaling pathways and factors from
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FIGURE 4 | Normal fibroblasts, but not myofibroblasts isolated from a
CD patient restrain the growth of cancer cells. (A,B) HCT116 and Hke-3
cells were cultured alone or in the presence of 30 or 50% of conditioned
medium from 18Co cells, intestinal myofibroblasts from a normal donor (HIF),
or from a patient with CD as indicated. MTT assay was performed as
described in the Section “Materials and Methods.” (C) Spheroids of HCT116
cells were generated using a hanging drop technique. Spheroids were
generated using control medium (10% MEM), medium containing 10%
conditioned medium from 18Co cells (10% CM-18Co) or THP1 macrophages
(10% CM-THP1). Alternatively, spheroids were generated by combining
HCT116 and 18Co cells (HCT116–18Co). #p<0.05, *p<0.005, compared to
control cells; NS, non-significant.
the normal stromal microenvironment that have the ability to
ameliorate or even reverse tumor progression.
In this study, we show that normal fibroblasts induce STAT1 sig-
naling and restrain the growth of colon cancer cells. Genome-wide
expression analysis revealed that fibroblasts induce the expression
of STAT1 and interferon-responsive genes also in breast cancer
cells, suggesting that interaction of breast cancer cells and fibrob-
lasts induces an interferon response (39). Surprisingly, however,
in that report the authors found that breast cancer patients with
high expression of STAT1 had worse prognosis. We demonstrated
that changes in the microenvironment, as they occur in inflam-
matory bowel disease alter the crosstalk between tumor cells
and fibroblasts and result in the inability of myofibroblasts iso-
lated from CD or UC patients to maintain the homeostasis of
the intestinal epithelium. We showed that myofibroblasts isolated
from CD or UC patients, who are at increased risk of develop-
ing colon cancer, were not able to induce STAT1 in carcinoma
cells and failed to inhibit their growth. Activation of 18Co cells
with TNF, a cytokine that plays a major role in the pathology of
CD, was sufficient to prevent STAT1 activation in carcinoma cells.
Finally, we confirmed that CAFs promote the growth of colon
cancer cells, in accord with their protumorigenic activity. Thus,
our data suggest an evolution of the tumor-associated stroma, in
which an early step is loss of the ability to restrain the growth
of the adjacent epithelium, followed by a gain of protumorigenic
function.
We show that intestinal fibroblasts inhibit the growth of carci-
noma cells (Figure 4), but have no significant effect on adhesion
of HCT116 cells on fibronectin, or on their migration (data not
shown). Our data suggest that K-Ras-transformed cells are more
sensitive to growth-inhibitory effects of fibroblast-derived factors,
although the induction of STAT1 signaling by fibroblasts was not
significantly affected by the presence of mutant K-Ras (Figure 2).
This is in contrast to our finding that IFN-induced STAT1 activity
is impaired in cells with oncogenic K-Ras (18, 40) and suggests
that in addition to STAT1 signaling, other pathways are likely to
contribute to the restrained growth of Ras-transformed cells in
the presence of fibroblasts. We showed that fibroblasts secrete a
number of soluble factors, but it is currently unknown which of
these factors is responsible for the activation of STAT1 in tumor
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FIGURE 5 | Cancer-associated myofibroblasts promote growth of tumor
cells. HCT116 (A) and Hke-3 cells (B) were cultured in the absence or the
presence of 25, 30, or 50% of condition medium from human
cancer-associated fibroblasts. MTT assay and BrdU incorporation were
performed as described in the Section “Materials and Methods” at 48 and
72 h of incubation. *p<0.05, compared to control cells.
FIGURE 6 | Fibroblasts inhibit growth of HCT116 cells in a
STAT1-dependent manner. (A) HCT116 cells were transfected with
non-specific (NSP) RNAi or with STAT1-specific RNAi and cell growth was
monitored in the absence (CTRL) or the presence of 30% or 50% conditioned
medium (CM) from 18Co cells by CellTiter-GLO Assay (Promega) at 24, 48,
72, and 96 h as indicated. (B) Silencing of STAT1 in HCT116 cells was
confirmed by immunoblotting. *p< 0.0001, #p=0.03, +p=0.0001, compared
to cells transfected with NSP RNAi.
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cells. CCL2, CXCL1, and IL6, produced by 18Co cells (Figure 3A)
could contribute to increased STAT1 activity in tumor cells.
We demonstrated that TNF inhibits the ability of fibroblasts
to induce growth-inhibitory STAT1 signaling in intestinal cells,
potentially contributing to the loss of growth-inhibitory activ-
ity of fibroblasts isolated from CD or UC patients. TNF, which
has been shown to activate intestinal fibroblasts (41, 42), plays a
major role in the pathogenesis of CD and inhibitors of TNF have
potent therapeutic activity (43). We show that TNF stimulates
the expression of a number of cytokines and chemokines, includ-
ing GM-CSF, IP10, CCL5, and IL6, but surprisingly it reduces
the synthesis of IL8 in 18Co cells (Figure 3A). Another conse-
quence of TNF stimulation is the expression of COX2 in 18Co
cells (Figure 3B), which is part of the proinflammatory signature
of CAFs (44). Although the mechanism whereby stimulation of
fibroblasts with TNF interferes with STAT1 activation in tumor
cells remains unknown, PGE2 has been shown to interfere with
STAT1 activity (45), and may therefore contribute to the inability
of TNF stimulated fibroblasts to activate STAT1 signaling in tumor
cells. TNF has also been shown to inhibit IFNα-activated STAT1
and inhibit IFNα signaling in the liver (46). It is likely that several
factors contribute to differential effects of normal fibroblasts and
CD myofibroblasts on the growth of intestinal cells. For example,
myofibroblasts isolated from patients with UC displayed signifi-
cantly lower expression of SFRP1, a Wnt inhibitor, which has been
shown to inhibit proliferation of IEC cells (47).
Because of their pivotal role in tumor progression, CAFs have
emerged as an important therapeutic target. They are genetically
stable and normalization of the tumor microenvironment is an
important venue to pursue in cancer chemoprevention and cancer
treatment.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at http://www.frontiersin.org/Journal/10.3389/fonc.2014.
00088/abstract
Figure S1 | Fibroblast-derived factors inhibit growth of rat intestinal cells.
Rat IEC-iKRasV12 cells were left untreated or were induced by IPTG to express
mutant K-Ras. The cells were cultured in the absence (CTRL) or the presence of
30 or 50% of conditioned medium from rat MIC216 intestinal fibroblasts. Cell
growth was monitored by the MTT assay (A) or BrdU incorporation (B). The
inhibitory effect of MIC216 cells was confirmed by co-culturing of IEC-iKRasV12
and MIC216 cells using transwells (C) and by demonstrating the reduced levels
of cyclin D1 (cyclD1) in intestinal cells grown in the presence of MIC216
fibroblasts (D). NSB, non-specific band.
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